研究室紹介Laboratories

Back
Top > 研究室紹介 > 病態外科学 > 消化器外科学

病態外科学消化器外科学

研究室概要

世界に通用する、優れた外科医を育成する

教室では、臨床においては教室伝統のがん手術の基本を忠実に受け継ぎつつ、機能温存・低侵襲手術から拡大根治手術に至るまで最新の外科治療を行っています。研究においてはがん遺伝子解析、抗がん剤感受性試験、ウイルス療法などがん治療の新たな可能性に向けて積極的に研究を行い、また豊富な臨床経験と最新の知見を持ち合わせた次世代を担う外科医の育成も目指しています。

全国的な外科医の減少傾向は社会問題に発展しておりますが、当教室では行政に先駆けて、若手外科医の修練環境の改善や女性医師の長期労働環境の整備を行っています。

また、若い医師に外科の魅力・やりがいを伝えるべく、努力しております。外科医は手術手技のみならず、多岐にわたる知識や技術と、重症患者およびその家族と協力して疾患に立ち向かう優れた人格が要求されます。その責任の重さゆえに味わえる充実感を、知識や技術とともにこれからの医療を担っていく若手医師に伝えていきたいと考えています。

当教室では各関連病院と密に連携し、まずは卒後6年目の外科学会専門医取得を前提とした、偏りのない総合的な臨床能力の育成を重視します。その後、卒後8年目に消化器外科学会専門医が取得できるよう多くの症例が経験できる環境を用意します。また、偏らない視野の広い外科医を育成すべく、なるべく多くの指導医から指導を受けられる修練環境の整備を心がけています。これらを礎とし、大学院医学研究科でのさらなる専門性の追求と、国内外へと発信する基礎・臨床研究につなげていきます。

高度な最先端の医療を実践しつつ、先人達から受け継いだ外科の伝統を融合させて「世界に通用する、優れた外科医を育成する」ことが、教室全体の目標であります。

研究プロジェクト

1. 食道グループ

  1. Tumor budding と食道扁平上皮癌に関する研究
  2. 食道癌に対する低侵襲手術(2領域郭清、胸腔内胃管吻合再建)
  3. 胃管再建不能食道癌症例に対する、有茎空腸再建手術
  4. 臨床病期 IB/II/III 食道癌(T4 を除く)に対する術前 CF 療法/術前 DCF 療法/ 術前 CF-RT 療法の第 III 相比較試験(JCOG1109)
  5. 術後管理法に関する新たな工夫(新たな腸瘻造設法・新たな胸腔ドレーン管理法等)

2. 胃グループ

  1. 新規胃癌腹膜播種特異的分子標的治療薬の開発
    腹膜播種は胃癌で高頻度かつ難治な転移再発様式です。当教室では、腹膜播種形成に特異的に関与する新規分子を同定し、これを標的とした腹腔内治療の開発を目指しています。マウス腹膜播種モデルでは、下図のように腹腔内治療群で著明な播種巣抑制効果を示しています。この治療法を実用化すべく、さらなる研究を行っています。

    project1.jpg

  2. 転移形式別Transcriptome解析による胃癌肝転移特異的バイオマーカーの研究
    肝転移に代表する胃癌の血行性転移は多くの分子が関与する多段階の過程を経て形成されることが知られていますが、その中には転移経路に特異的な分子が存在すると考えています。そこで、肝転移・再発をきたした症例に特異的に発現異常を認める分子を網羅的発現解析から同定し、その胃癌肝転移診断・予測バイオマーカーとしての有用性を研究しています。

    project2.jpg

  3. ICGによる新しい早期胃癌マーキング法の研究
  4. 胃癌手術における高齢者機能評価に関する研究
  5. 内視鏡手術シミュレーション訓練の新しい統合的基本タスク作成
  6. 手術時における術者の疲労、ストレスの客観的測定法の研究
  7. 腹膜播種を伴う胃癌に対する腹腔内化学療法の開発
    腹膜播種は胃癌の中で最も頻度の高い進行再発形式です。近年、腹膜播種に対する腹腔内化学療法の治療効果が報告されています。抗癌剤を腹腔内に投与する方法は、直接的な抗腫瘍効果が大きな利点であり、従来の全身化学療法と併用することで治療成績を改善することが期待されます。当科は腹腔内化学療法研究会の参加施設であり、先進医療下の臨床試験として多施設共同試験に参加、および主たる研究機関として腹腔内化学療法の確立を目指しています。

    project3.jpg

  8. 実臨床における胃癌化学療法バイオマーカーの探索的研究
    胃癌化学療法における二次治療の一つであるnab-paclitaxel療法のバイオマーカーとしてSPARC(secreted protein acidic and rich in cysteine)に着目し、治療効果とSPARC発現との関連を研究しています。SPARCは細胞間質における非構造性のマトリックス糖蛋白で胃癌でも高頻度に高発現していることが報告されており、アルブミン親和性が高いことが知られています。paclitaxelとヒト血清アルブミンを結合させたnab-paclitaxelの腫瘍内への集積は,SPARCが媒介していると考えられていることから,SPARC発現とnab-paclitaxelの有効性の検討を行っています。

    project4.jpg

3. 肝臓グループ

  1. エピジェネティクスにより制御される肝細胞癌関連遺伝子の同定と機能解析
  2. 肝疾患における肝血流動態解析
  3. 周術期全身超音波診断法の臨床研究
    Point-of-care ultrasonogrphy(POCUS)の概念が提唱され、欧米では急速に臨床応用が広がっている。当研究室ではPOCUSの周術期管理への応用につき検討しています。

    project5.jpg

  4. 超音波ナビゲーション装置を用いた肝切除法の開発

4. 膵臓グループ

  1. 局所進行膵癌における術前治療(S-1併用放射線療法など)
  2. 術後合併症軽減をめざした新たな外科手技の導入(Blumgart変法など)
  3. 膵頭部癌に対する膵頭十二指腸切除術における上腸間膜動脈周囲神経叢右半周郭清に関するランダム化第Ⅱ相試験
  4. Borderline resectable膵癌に対するFOLFIRINOXまたはnab-paclitaxel + gemcitabine術前補助化学療法のランダム化第II相試験
  5. 膵体尾部切除での膵実質切断における脾静脈剥離-個別処理と脾静脈同時切断の多施設共同無作為化比較第Ⅲ相試験- COSMOS-DP trial
  6. 局所進行切除不能膵癌に対するゲムシタビンおよびnabパクリタキセル併用化学放射線療法の第I相臨床試験Nagoya University Pancreatic Tumor Board trial 02(NUPAT-02)
  7. 腹膜転移を有する膵癌に対するGemcitabine (GEM) +nab-Paclitaxel (PTX)+ PTX腹腔内投与併用療法の第I/II相多施設共同臨床試験
  8. 膵癌切除後の腹膜再発(ゲムシタビンとフッ化ピリミジン系抗癌剤不応)に対するパクリタキセル経静脈・腹腔内併用療法の治療効果を検証するための第I/Ⅱ相臨床試験
  9. 膵癌における補助化学療法の個別化に向けた取り組み
  10. 膵腫瘍における新規予後因子発見に関する探索的研究
  11. 膵癌における癌浸潤・転移メカニズムの解明(上皮間葉転換など)

5. 大腸グループ

  1. High-risk Stage Ⅱ / Stage Ⅲ 大腸癌術後補助化学療法としてのCapeOX 療法におけるオキサリプラチン間欠投与と継続投与の有効性と安全性を評価する無作為化第Ⅱ相臨床試験(CCOG1302)
  2. RAS 遺伝子野生型潜在的切除可能進行再発大腸癌に対する切除を目指した治療戦略において、Panitumumab + mFOLFOX 6 療法の早期腫瘍縮小効果について検討し、本レジメンでのR0切除率との関連を検索する多施設共同観察研究(CCOG1401)
  3. クローン病術後抗TNF-α抗体維持療法の有効性と安全性に関する検討
  4. 進行再発大腸癌に対する化学療法における新たなsurrogate markerの開発

    project6.jpg

教員

構成員名役職所属
小寺 泰弘 教授 消化器外科学
藤原 道隆 准教授 クリニカルシミュレーションセンター・消化器外科学
小池 聖彦 講師 消化器外科学
中山 吾郎 講師 消化器外科学
山田 豪 講師 消化器外科学
小林 大介 講師・医局長 消化器外科学
田中 千恵 講師 消化器外科学
丹羽 由紀子 講師 医療の質安全管理部・消化器外科学
岩田 直樹 助教 救急・集中治療医学
神田 光郎 助教 消化器外科学
林 真路 助教 消化器外科学
高見 秀樹 助教 消化器外科学
服部 憲史 助教 消化器外科学
末永 雅也 助教 消化器外科学
園原 史訓 助教 消化器外科学

研究実績

  • 2016年
    1. Asano T, Natsume S, Senda Y, Sano T, Matsuo K, Kodera Y, et al. Incidence and risk factors for anastomotic stenosis of continuous hepaticojejunostomy after pancreaticoduodenectomy. J Hepatobiliary Pancreat Sci, 2016; 23: 628-635.
    2. Inokawa Y, Sonohara F, Kanda M, Hayashi M, Nishikawa Y, Sugimoto H, et al. Correlation Between Poor Prognosis and Lower TPPP Gene Expression in Hepatocellular Carcinoma. Anticancer Res, 2016; 36: 4639-4645.
    3. Kanda M, Shimizu D, Fujii T, Tanaka H, Tanaka Y, Ezaka K, et al. Neurotrophin Receptor-Interacting Melanoma Antigen-Encoding Gene Homolog is Associated with Malignant Phenotype of Gastric Cancer. Ann Surg Oncol, 2016; 23: 532-539.
    4. Kanda M, Tanaka C, Kobayashi D, Mizuno A, Tanaka Y, Takami H, et al. Proposal of the Coagulation Score as a Predictor for Short-Term and Long-Term Outcomes of Patients with Resectable Gastric Cancer. Ann Surg Oncol, 2016.
    5. Kanda M, Tanaka C, Kobayashi D, Tanaka H, Shimizu D, Shibata M, et al. Epigenetic suppression of the immunoregulator MZB1 is associated with the malignant phenotype of gastric cancer. Int J Cancer, 2016; 139: 2290-2298.
    6. Nakayama G, Fujii T, Murotani K, Uehara K, Hattori N, Hayashi M, et al. Modified two-dimensional response as surrogate marker of overall survival in patients with metastatic colorectal cancer. Cancer Sci, 2016.
    7. Nishikawa K, Takahashi T, Takaishi H, Miki A, Noshiro H, Yoshikawa T, et al. Phase II study of the effectiveness and safety of trastuzumab and paclitaxel for taxane- and trastuzumab-naive patients with HER2-positive, previously treated, advanced, or recurrent gastric cancer (JFMC45-1102). Int J Cancer, 2016.
    8. Tanaka H, Kanda M, Shimizu D, Tanaka C, Kobayashi D, Hayashi M, et al. FAM46C Serves as a Predictor of Hepatic Recurrence in Patients with Resectable Gastric Cancer. Ann Surg Oncol, 2016.
    9. Tanaka Y, Kanda M, Tanaka C, Kobayashi D, Mizuno A, Iwata N, et al. Usefulness of preoperative estimated glomerular filtration rate to predict complications after curative gastrectomy in patients with clinical T2-4 gastric cancer. Gastric Cancer, 2016.
    10. Yabusaki N, Fujii T, Yamada S, Murotani K, Sugimoto H, Kanda M, et al. The significance of relative dose intensity in adjuvant chemotherapy of pancreatic ductal adenocarcinoma-including the analysis of clinicopathological factors influencing relative dose intensity. Medicine (Baltimore), 2016; 95: e4282.
    11. Fujii T, Satoi S, Yamada S, Murotani K, Yanagimoto H, Takami H, et al. Clinical benefits of neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreatic head: an observational study using inverse probability of treatment weighting. J Gastroenterol, 2016.
    12. Kanda M, Mizuno A, Tanaka C, Kobayashi D, Fujiwara M, Iwata N, et al. Nutritional predictors for postoperative short-term and long-term outcomes of patients with gastric cancer. Medicine (Baltimore), 2016; 95: e3781.
    13. Kanda M, Shimizu D, Fujii T, Tanaka H, Shibata M, Iwata N, et al. Protein arginine methyltransferase 5 is associated with malignant phenotype and peritoneal metastasis in gastric cancer. Int J Oncol, 2016; 49: 1195-1202.
    14. Niwa Y, Koike M, Hattori M, Iwata N, Takami H, Hayashi M, et al. Short-term outcomes after conventional transthoracic esophagectomy. Nagoya J Med Sci, 2016; 78: 69-78.
    15. Shimizu D, Kanda M, Sugimoto H, Sueoka S, Takami H, Ezaka K, et al. NRAGE promotes the malignant phenotype of hepatocellular carcinoma. Oncol Lett, 2016; 11: 1847-1854.
    16. Suenaga M, Yamada S, Fujii T, Tanaka C, Kanda M, Nakayama G, et al. S-1 plus nab-paclitaxel is a promising regimen for pancreatic cancer in a preclinical model. J Surg Oncol, 2016; 113: 413-419.
    17. Yabusaki N, Fujii T, Yamada S, Suzuki K, Sugimoto H, Kanda M, et al. Adverse impact of low skeletal muscle index on the prognosis of hepatocellular carcinoma after hepatic resection. Int J Surg, 2016; 30: 136-142.
    18. Yamada S, Fujii T, Hirakawa A, Kanda M, Sugimoto H, Kodera Y. Lymph node ratio as parameter of regional lymph node involvement in pancreatic cancer. Langenbecks Arch Surg, 2016.
    19. Yamada S, Fujii T, Yabusaki N, Murotani K, Iwata N, Kanda M, et al. Clinical Implication of Inflammation-Based Prognostic Score in Pancreatic Cancer: Glasgow Prognostic Score Is the Most Reliable Parameter. Medicine (Baltimore), 2016; 95: e3582.
    20. Satoi S, Fujii T, Yanagimoto H, Motoi F, Kurata M, Takahara N, et al. Multicenter Phase II Study of Intravenous and Intraperitoneal Paclitaxel With S-1 for Pancreatic Ductal Adenocarcinoma Patients With Peritoneal Metastasis. Ann Surg, 2016.
    21. Okada K, Kawai M, Hirono S, Fujii T, Kodera Y, Sho M, et al. Evaluation of the efficacy of daikenchuto (TJ -100) for the prevention of paralytic ileus after pancreaticoduodenectomy: A multicenter, double-blind, randomized, placebo-controlled trial. Surgery, 2016; 159: 1333-1341.
    22. Mizuno A, Kanda M, Kobayashi D, Tanaka C, Iwata N, Yamada S, et al. Adverse Effects of Intraoperative Blood Loss on Long-Term Outcomes after Curative Gastrectomy of Patients with Stage II/III Gastric Cancer. Dig Surg, 2016; 33: 121-128.
    23. Kodera Y, Takahashi N, Yoshikawa T, Takiguchi N, Fujitani K, Ito Y, et al. Feasibility of weekly intraperitoneal versus intravenous paclitaxel therapy delivered from the day of radical surgery for gastric cancer: a preliminary safety analysis of the INPACT study, a randomized controlled trial. Gastric Cancer, 2016.
    24. Kanda M, Shimizu D, Tanaka H, Shibata M, Iwata N, Hayashi M, et al. Metastatic pathway-specific transcriptome analysis identifies MFSD4 as a putative tumor suppressor and biomarker for hepatic metastasis in patients with gastric cancer. Oncotarget, 2016; 7: 13667-13679.
    25. Kanda M, Mizuno A, Fujii T, Shimoyama Y, Yamada S, Tanaka C, et al. Tumor Infiltrative Pattern Predicts Sites of Recurrence After Curative Gastrectomy for Stages 2 and 3 Gastric Cancer. Ann Surg Oncol, 2016; 23: 1934-1940.
    26. Kanda M, Fujiwara M, Tanaka C, Kobayashi D, Iwata N, Mizuno A, et al. Predictive value of drain amylase content for peripancreatic inflammatory fluid collections after laparoscopic (assisted) distal gastrectomy. Surg Endosc, 2016; 30: 4353-4362.
    27. Kamiya T, Uehara K, Nakayama G, Ishigure K, Kobayashi S, Hiramatsu K, et al. Early results of multicenter phase II trial of perioperative oxaliplatin and capecitabine without radiotherapy for high-risk rectal cancer: CORONA I study. Eur J Surg Oncol, 2016; 42: 829-835.
    28. Hayashi N, Ando Y, Gyawali B, Shimokata T, Maeda O, Fukaya M, et al. Low skeletal muscle density is associated with poor survival in patients who receive chemotherapy for metastatic gastric cancer. Oncol Rep, 2016; 35: 1727-1731.
    29. Yoshida K, Yamaguchi K, Okumura N, Tanahashi T, Kodera Y. Is conversion therapy possible in stage IV gastric cancer: the proposal of new biological categories of classification. Gastric Cancer, 2016; 19: 329-338.
    30. Yamada S, Fujii T, Suzuki K, Inokawa Y, Kanda M, Nakayama G, et al. Preoperative Identification of a Prognostic Factor for Pancreatic Neuroendocrine Tumors Using Multiphase Contrast-Enhanced Computed Tomography. Pancreas, 2016; 45: 198-203.
    31. Yamada S, Fujii T, Murotani K, Kanda M, Sugimoto H, Nakayama G, et al. Comparison of the international consensus guidelines for predicting malignancy in intraductal papillary mucinous neoplasms. Surgery, 2016; 159: 878-884.
    32. Tanigawa N, Yamaue H, Ohyama S, Sakuramoto S, Inada T, Kodera Y, et al. Exploratory phase II trial in a multicenter setting to evaluate the clinical value of a chemosensitivity test in patients with gastric cancer (JACCRO-GC 04, Kubota memorial trial). Gastric Cancer, 2016; 19: 350-360.
    33. Nakanishi K, Kobayashi D, Mochizuki Y, Ishigure K, Ito S, Kojima H, et al. Phase II multi-institutional prospective randomized trial comparing S-1 plus paclitaxel with paclitaxel alone as second-line chemotherapy in S-1 pretreated gastric cancer (CCOG0701). Int J Clin Oncol, 2016; 21: 557-565.
    34. Matsusaka S, Nashimoto A, Nishikawa K, Miki A, Miwa H, Yamaguchi K, et al. Erratum to: Clinicopathological factors associated with HER2 status in gastric cancer: results from a prospective multicenter observational cohort study in a Japanese population (JFMC44-1101). Gastric Cancer, 2016; 19: 1026.
    35. Fujii T, Yamada S, Murotani K, Sugimoto H, Hattori M, Kanda M, et al. Modified Blumgart Suturing Technique for Remnant Closure After Distal Pancreatectomy: a Propensity Score-Matched Analysis. J Gastrointest Surg, 2016; 20: 374-384.
    36. Oya H, Kanda M, Koike M, Iwata N, Niwa Y, Shimizu D, et al. Detection of serum melanoma-associated antigen D4 in patients with squamous cell carcinoma of the esophagus. Dis Esophagus, 2016; 29: 663-669.
    37. Baiocchi GL, D'Ugo D, Coit D, Hardwick R, Kassab P, Nashimoto A, et al. Follow-up after gastrectomy for cancer: the Charter Scaligero Consensus Conference. Gastric Cancer, 2016; 19: 15-20.
    38. Kanda M, Nomoto S, Oya H, Takami H, Shimizu D, Hibino S, et al. The Expression of Melanoma-Associated Antigen D2 Both in Surgically Resected and Serum Samples Serves as Clinically Relevant Biomarker of Gastric Cancer Progression. Ann Surg Oncol, 2016; 23 Suppl 2: S214-221.
    39. Niwa Y, Koike M, Hattori M, Iwata N, Takami H, Hayashi M, et al. The Prognostic Relevance of Subcarinal Lymph Node Dissection in Esophageal Squamous Cell Carcinoma. Ann Surg Oncol, 2016; 23: 611-618.
    40. Niwa Y, Koike M, Fujimoto Y, Oya H, Iwata N, Nishio N, et al. Salvage pharyngolaryngectomy with total esophagectomy following definitive chemoradiotherapy. Dis Esophagus, 2016; 29: 598-602.
    41. Kanda M, Shimizu D, Fujii T, Sueoka S, Tanaka Y, Ezaka K, et al. Function and diagnostic value of Anosmin-1 in gastric cancer progression. Int J Cancer, 2016; 138: 721-730.
    42. Ito Y, Yoshikawa T, Fujiwara M, Kojima H, Matsui T, Mochizuki Y, et al. Quality of life and nutritional consequences after aboral pouch reconstruction following total gastrectomy for gastric cancer: randomized controlled trial CCOG1101. Gastric Cancer, 2016; 19: 977-985.
    43. Kanda M, Kobayashi D, Tanaka C, Iwata N, Yamada S, Fujii T, et al. Adverse prognostic impact of perioperative allogeneic transfusion on patients with stage II/III gastric cancer. Gastric Cancer, 2016; 19: 255-263.
    44. Fujita J, Takahashi M, Urushihara T, Tanabe K, Kodera Y, Yumiba T, et al. Assessment of postoperative quality of life following pylorus-preserving gastrectomy and Billroth-I distal gastrectomy in gastric cancer patients: results of the nationwide postgastrectomy syndrome assessment study. Gastric Cancer, 2016; 19: 302-311.
  • 2015年
    1. Fujii T, Yamada S, Murotani K, Okamura Y, Ishigure K, Kanda M, et al. Oral Food Intake Versus Fasting on Postoperative Pancreatic Fistula After Distal Pancreatectomy: A Multi-Institutional Randomized Controlled Trial. Medicine (Baltimore), 2015; 94: e2398.
    2. Tanaka H, Kanda M, Koike M, Iwata N, Shimizu D, Ezaka K, et al. Adherens junctions associated protein 1 serves as a predictor of recurrence of squamous cell carcinoma of the esophagus. Int J Oncol, 2015; 47: 1811-1818.
    3. Suenaga M, Yamada S, Fuchs BC, Fujii T, Kanda M, Tanaka C, et al. CD44 single nucleotide polymorphism and isoform switching may predict gastric cancer recurrence. J Surg Oncol, 2015; 112: 622-628.
    4. Fujii T, Yamada S, Murotani K, Kanda M, Sugimoto H, Nakao A, et al. Inverse Probability of Treatment Weighting Analysis of Upfront Surgery Versus Neoadjuvant Chemoradiotherapy Followed by Surgery for Pancreatic Adenocarcinoma with Arterial Abutment. Medicine (Baltimore), 2015; 94: e1647.
    5. Yabusaki N, Yamada S, Shimoyama Y, Fujii T, Kanda M, Nakayama G, et al. A vascular endothelial growth factor gene polymorphism predicts malignant potential in intraductal papillary mucinous neoplasm. Pancreas, 2015; 44: 608-614.
    6. Yabusaki N, Yamada S, Murai T, Kanda M, Kobayashi D, Tanaka C, et al. Clinical significance of zinc-finger E-box binding homeobox 1 mRNA levels in peritoneal washing for gastric cancer. Mol Clin Oncol, 2015; 3: 435-441.
    7. Tanaka Y, Kanda M, Sugimoto H, Shimizu D, Sueoka S, Takami H, et al. Translational implication of Kallmann syndrome-1 gene expression in hepatocellular carcinoma. Int J Oncol, 2015; 46: 2546-2554.
    8. Sueoka S, Kanda M, Sugimoto H, Shimizu D, Nomoto S, Oya H, et al. Suppression of SAMSN1 Expression is Associated with the Malignant Phenotype of Hepatocellular Carcinoma. Ann Surg Oncol, 2015; 22 Suppl 3: S1453-1460.
    9. Nakamura M, Wakabayashi G, Miyasaka Y, Tanaka M, Morikawa T, Unno M, et al. Multicenter comparative study of laparoscopic and open distal pancreatectomy using propensity score-matching. J Hepatobiliary Pancreat Sci, 2015; 22: 731-736.
    10. Kanda M, Murotani K, Kobayashi D, Tanaka C, Yamada S, Fujii T, et al. Postoperative adjuvant chemotherapy with S-1 alters recurrence patterns and prognostic factors among patients with stage II/III gastric cancer: A propensity score matching analysis. Surgery, 2015; 158: 1573-1580.
    11. Fujii T, Kanda M, Nagai S, Suenaga M, Takami H, Yamada S, et al. Excess Weight Adversely Influences Treatment Length of Postoperative Pancreatic Fistula: A Retrospective Study of 900 Patients. Pancreas, 2015; 44: 971-976.
    12. Ezaka K, Kanda M, Sugimoto H, Shimizu D, Oya H, Nomoto S, et al. Reduced Expression of Adherens Junctions Associated Protein 1 Predicts Recurrence of Hepatocellular Carcinoma After Curative Hepatectomy. Ann Surg Oncol, 2015; 22 Suppl 3: S1499-1507.
    13. Yamada S, Fujii T, Shimoyama Y, Kanda M, Nakayama G, Sugimoto H, et al. SMAD4 expression predicts local spread and treatment failure in resected pancreatic cancer. Pancreas, 2015; 44: 660-664.
    14. Nomoto H, Takami A, Espinoza JL, Matsuo K, Mizuno S, Onizuka M, et al. A donor thrombomodulin gene variation predicts graft-versus-host disease development and mortality after bone marrow transplantation. Int J Hematol, 2015; 102: 460-470.
    15. Nomoto H, Takami A, Espinoza JL, Matsuo K, Mizuno S, Onizuka M, et al. Erratum to: A donor thrombomodulin gene variation predicts graft-versus-host disease development and mortality after bone marrow transplantation. Int J Hematol, 2015; 102: 507-508.
    16. Kobayashi D, Iwata N, Tanaka C, Kanda M, Yamada S, Nakayama G, et al. Factors related to occurrence and aggravation of pancreatic fistula after radical gastrectomy for gastric cancer. J Surg Oncol, 2015; 112: 381-386.
    17. Hattori N, Yamada S, Torii K, Takeda S, Nakamura K, Tanaka H, et al. Effectiveness of plasma treatment on pancreatic cancer cells. Int J Oncol, 2015; 47: 1655-1662.
    18. Hattori M, Fujii T, Yamada S, Inokawa Y, Suenaga M, Takami H, et al. Significance of the Splenic Vein and Its Branches in Pancreatoduodenectomy with Resection of the Portal Vein System. Dig Surg, 2015; 32: 382-388.
    19. Takano N, Hishida M, Inokawa Y, Hayashi M, Kanda M, Nishikawa Y, et al. CCNJ detected by triple combination array analysis as a tumor-related gene of hepatocellular carcinoma. Int J Oncol, 2015; 46: 1963-1970.
    20. Sonohara F, Nomoto S, Inokawa Y, Kanda M, Yamada S, Fujii T, et al. Serosal invasion strongly associated with recurrence after curative hepatic resection of hepatocellular carcinoma: a retrospective study of 214 consecutive cases. Medicine (Baltimore), 2015; 94: e602.
    21. Oya H, Koike M, Iwata N, Kobayashi D, Torii K, Niwa Y, et al. Feeding duodenostomy decreases the incidence of mechanical obstruction after radical esophageal cancer surgery. World J Surg, 2015; 39: 1105-1110.
    22. Hishida M, Inokawa Y, Takano N, Nishikawa Y, Iwata N, Kanda M, et al. Protein tyrosine kinase 7: a hepatocellular carcinoma-related gene detected by triple-combination array. J Surg Res, 2015; 195: 444-453.
    23. Hashimoto R, Kanda M, Takami H, Shimizu D, Oya H, Hibino S, et al. Aberrant expression of melanoma-associated antigen-D2 serves as a prognostic indicator of hepatocellular carcinoma outcome following curative hepatectomy. Oncol Lett, 2015; 9: 1201-1206.
    24. Fujii T, Nakao A, Yamada S, Suenaga M, Hattori M, Takami H, et al. Vein resections >3 cm during pancreatectomy are associated with poor 1-year patency rates. Surgery, 2015; 157: 708-715.
    25. Fujii T, Nakao A, Murotani K, Okamura Y, Ishigure K, Hatsuno T, et al. Influence of Food Intake on the Healing Process of Postoperative Pancreatic Fistula After Pancreatoduodenectomy: A Multi-institutional Randomized Controlled Trial. Ann Surg Oncol, 2015; 22: 3905-3912.
    26. Sonohara F, Nomoto S, Inokawa Y, Hishida M, Takano N, Kanda M, et al. High expression of Janus kinase 2 in background normal liver tissue of resected hepatocellular carcinoma is associated with worse prognosis. Oncol Rep, 2015; 33: 767-773.
    27. Niwa Y, Koike M, Oya H, Iwata N, Kobayashi D, Kanda M, et al. Method of bilateral pleural drainage by single Blake drain after esophagectomy. World J Surg, 2015; 39: 727-731.
    28. Kawahira H, Kodera Y, Hiki N, Takahashi M, Itoh S, Mitsumori N, et al. Optimal Roux-en-Y reconstruction after distal gastrectomy for early gastric cancer as assessed using the newly developed PGSAS-45 scale. Surg Today, 2015; 45: 1307-1316.
    29. Kanda M, Sugimoto H, Nomoto S, Oya H, Hibino S, Shimizu D, et al. Bcell translocation gene 1 serves as a novel prognostic indicator of hepatocellular carcinoma. Int J Oncol, 2015; 46: 641-648.
    30. Kanda M, Oya H, Nomoto S, Takami H, Shimizu D, Hashimoto R, et al. Diversity of clinical implication of B-cell translocation gene 1 expression by histopathologic and anatomic subtypes of gastric cancer. Dig Dis Sci, 2015; 60: 1256-1264.
    31. Fujii T, Yamada S, Suenaga M, Kanda M, Takami H, Sugimoto H, et al. Preoperative internal biliary drainage increases the risk of bile juice infection and pancreatic fistula after pancreatoduodenectomy: a prospective observational study. Pancreas, 2015; 44: 465-470.
    32. Torii K, Yamada S, Nakamura K, Tanaka H, Kajiyama H, Tanahashi K, et al. Effectiveness of plasma treatment on gastric cancer cells. Gastric Cancer, 2015; 18: 635-643.
    33. Tan G, Kasuya H, Sahin TT, Yamamura K, Wu Z, Koide Y, et al. Combination therapy of oncolytic herpes simplex virus HF10 and bevacizumab against experimental model of human breast carcinoma xenograft. Int J Cancer, 2015; 136: 1718-1730.
    34. Oya H, Kanda M, Sugimoto H, Shimizu D, Takami H, Hibino S, et al. Dihydropyrimidinase-like 3 is a putative hepatocellular carcinoma tumor suppressor. J Gastroenterol, 2015; 50: 590-600.
    35. Takiguchi N, Takahashi M, Ikeda M, Inagawa S, Ueda S, Nobuoka T, et al. Long-term quality-of-life comparison of total gastrectomy and proximal gastrectomy by postgastrectomy syndrome assessment scale (PGSAS-45): a nationwide multi-institutional study. Gastric Cancer, 2015; 18: 407-416.
    36. Namikawa T, Hiki N, Kinami S, Okabe H, Urushihara T, Kawahira H, et al. Factors that minimize postgastrectomy symptoms following pylorus-preserving gastrectomy: assessment using a newly developed scale (PGSAS-45). Gastric Cancer, 2015; 18: 397-406.
    37. Misawa K, Fujiwara M, Ando M, Ito S, Mochizuki Y, Ito Y, et al. Long-term quality of life after laparoscopic distal gastrectomy for early gastric cancer: results of a prospective multi-institutional comparative trial. Gastric Cancer, 2015; 18: 417-425.
    38. Kurimoto K, Ishigure K, Mochizuki Y, Ishiyama A, Matsui T, Ito S, et al. A feasibility study of postoperative chemotherapy with S-1 and cisplatin (CDDP) for stage III/IV gastric cancer (CCOG 1106). Gastric Cancer, 2015; 18: 354-359.
    39. Kanda M, Shimizu D, Nomoto S, Takami H, Hibino S, Oya H, et al. Prognostic impact of expression and methylation status of DENN/MADD domain-containing protein 2D in gastric cancer. Gastric Cancer, 2015; 18: 288-296.
    40. Nakada K, Ikeda M, Takahashi M, Kinami S, Yoshida M, Uenosono Y, et al. Characteristics and clinical relevance of postgastrectomy syndrome assessment scale (PGSAS)-45: newly developed integrated questionnaires for assessment of living status and quality of life in postgastrectomy patients. Gastric Cancer, 2015; 18: 147-158.
    41. Oya H, Kanda M, Takami H, Hibino S, Shimizu D, Niwa Y, et al. Overexpression of melanoma-associated antigen D4 is an independent prognostic factor in squamous cell carcinoma of the esophagus. Dis Esophagus, 2015; 28: 188-195.
    42. Kodera Y. More than 6 months of postoperative adjuvant chemotherapy results in loss of skeletal muscle: a challenge to the current standard of care. Gastric Cancer, 2015; 18: 203-204.
    43. Kodera Y, Kobayashi D, Tanaka C, Fujiwara M. Gastric adenocarcinoma with para-aortic lymph node metastasis: a borderline resectable cancer? Surg Today, 2015; 45: 1082-1090.
  • 2014年
    1. Suenaga M, Fujii T, Kanda M, Takami H, Okumura N, Inokawa Y, et al. Pattern of first recurrent lesions in pancreatic cancer: hepatic relapse is associated with dismal prognosis and portal vein invasion. Hepatogastroenterology, 2014; 61: 1756-1761.
    2. Niwa Y, Koike M, Iwata N, Kobayashi D, Tanaka C, Fujii T, et al. Effect of landiolol hydrochloride on tachyarrhythmia after esophagectomy. Hepatogastroenterology, 2014; 61: 1546-1551.
    3. Kanda M, Sugimoto H, Nomoto S, Oya H, Shimizu D, Takami H, et al. Clinical utility of PDSS2 expression to stratify patients at risk for recurrence of hepatocellular carcinoma. Int J Oncol, 2014; 45: 2005-2012.
    4. Kanda M, Nomoto S, Oya H, Shimizu D, Takami H, Hibino S, et al. Dihydropyrimidinase-like 3 facilitates malignant behavior of gastric cancer. J Exp Clin Cancer Res, 2014; 33: 66.
    5. Kanda M, Nomoto S, Oya H, Hashimoto R, Takami H, Shimizu D, et al. Decreased expression of prenyl diphosphate synthase subunit 2 correlates with reduced survival of patients with gastric cancer. J Exp Clin Cancer Res, 2014; 33: 88.
    6. Kanda M, Fujii T, Takami H, Suenaga M, Inokawa Y, Yamada S, et al. Novel diagnostics for aggravating pancreatic fistulas at the acute phase after pancreatectomy. World J Gastroenterol, 2014; 20: 8535-8544.
    7. Kanda M, Fujii T, Suenaga M, Takami H, Hattori M, Inokawa Y, et al. Estimated pancreatic parenchymal remnant volume accurately predicts clinically relevant pancreatic fistula after pancreatoduodenectomy. Surgery, 2014; 156: 601-610.
    8. Inokawa Y, Sugimoto H, Kanda M, Yamada S, Fujii T, Nomoto S, et al. Hepatectomy for hepatocellular carcinoma in patients with hemophilia. J Hepatobiliary Pancreat Sci, 2014; 21: 824-828.
    9. Baiocchi GL, Kodera Y, Marrelli D, Pacelli F, Morgagni P, Roviello F, et al. Follow-up after gastrectomy for cancer: results of an international web round table. World J Gastroenterol, 2014; 20: 11966-11971.
    10. Yamamura K, Sugimoto H, Kanda M, Yamada S, Nomoto S, Nakayama G, et al. Comparison of inflammation-based prognostic scores as predictors of tumor recurrence in patients with hepatocellular carcinoma after curative resection. J Hepatobiliary Pancreat Sci, 2014; 21: 682-688.
    11. Yamada S, Okumura N, Wei L, Fuchs BC, Fujii T, Sugimoto H, et al. Epithelial to mesenchymal transition is associated with shorter disease-free survival in hepatocellular carcinoma. Ann Surg Oncol, 2014; 21: 3882-3890.
    12. Nomoto S, Hishida M, Inokawa Y, Sugimoto H, Kodera Y. Management of hepatocellular carcinoma should consider both tumor factors and background liver factors. Hepatobiliary Surg Nutr, 2014; 3: 82-85.
    13. Niwa Y, Yamada S, Koike M, Kanda M, Fujii T, Nakayama G, et al. Epithelial to mesenchymal transition correlates with tumor budding and predicts prognosis in esophageal squamous cell carcinoma. J Surg Oncol, 2014; 110: 764-769.
    14. Mashita N, Yamada S, Nakayama G, Tanaka C, Iwata N, Kanda M, et al. Epithelial to mesenchymal transition might be induced via CD44 isoform switching in colorectal cancer. J Surg Oncol, 2014; 110: 745-751.
    15. Kasuya H, Kodera Y, Nakao A, Yamamura K, Gewen T, Zhiwen W, et al. Phase I Dose-escalation Clinical Trial of HF10 Oncolytic Herpes Virus in 17 Japanese Patients with Advanced Cancer. Hepatogastroenterology, 2014; 61: 599-605.
    16. Yamada S, Fujii T, Shimoyama Y, Kanda M, Nakayama G, Sugimoto H, et al. Clinical implication of morphological subtypes in management of intraductal papillary mucinous neoplasm. Ann Surg Oncol, 2014; 21: 2444-2452.
    17. Nomoto S, Hishida M, Inokawa Y, Takano N, Kanda M, Nishikawa Y, et al. Expression analysis of THOP1 in background liver, a prognostic predictive factor in hepatocellular carcinoma, extracted by multiarray analysis. Ann Surg Oncol, 2014; 21 Suppl 3: S443-450.
    18. Nakayama G, Tanaka C, Uehara K, Mashita N, Hayashi N, Kobayashi D, et al. The impact of dose/time modification in irinotecan- and oxaliplatin-based chemotherapies on outcomes in metastatic colorectal cancer. Cancer Chemother Pharmacol, 2014; 73: 847-855.
    19. Kanda M, Shimizu D, Nomoto S, Hibino S, Oya H, Takami H, et al. Clinical significance of expression and epigenetic profiling of TUSC1 in gastric cancer. J Surg Oncol, 2014; 110: 136-144.
    20. Kanda M, Fujii T, Suenaga M, Takami H, Inokawa Y, Yamada S, et al. Pancreatoduodenectomy with portal vein resection is feasible and potentially beneficial for elderly patients with pancreatic cancer. Pancreas, 2014; 43: 951-958.
    21. Hirabayashi S, Kosugi S, Isobe Y, Nashimoto A, Oda I, Hayashi K, et al. Development and external validation of a nomogram for overall survival after curative resection in serosa-negative, locally advanced gastric cancer. Ann Oncol, 2014; 25: 1179-1184.
    22. Hayashi M, Nomoto S, Hishida M, Inokawa Y, Kanda M, Okamura Y, et al. Identification of the collagen type 1 alpha 1 gene (COL1A1) as a candidate survival-related factor associated with hepatocellular carcinoma. BMC Cancer, 2014; 14: 108.
    23. Fujii T, Sugimoto H, Yamada S, Kanda M, Suenaga M, Takami H, et al. Modified Blumgart anastomosis for pancreaticojejunostomy: technical improvement in matched historical control study. J Gastrointest Surg, 2014; 18: 1108-1115.
    24. Yamamura K, Kasuya H, Sahin TT, Tan G, Hotta Y, Tsurumaru N, et al. Combination treatment of human pancreatic cancer xenograft models with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib and oncolytic herpes simplex virus HF10. Ann Surg Oncol, 2014; 21: 691-698.
    25. Takami H, Fujii T, Kanda M, Suenaga M, Yamamura K, Kodera Y. Preservation of the pyloric ring confers little benefit in patients undergoing total pancreatectomy. World J Surg, 2014; 38: 1807-1813.
    26. Shimizu D, Kanda M, Nomoto S, Oya H, Takami H, Hibino S, et al. Identification of intragenic methylation in the TUSC1 gene as a novel prognostic marker of hepatocellular carcinoma. Oncol Rep, 2014; 31: 1305-1313.
    27. Murai T, Yamada S, Fuchs BC, Fujii T, Nakayama G, Sugimoto H, et al. Epithelial-to-mesenchymal transition predicts prognosis in clinical gastric cancer. J Surg Oncol, 2014; 109: 684-689.
    28. Misawa K, Mochizuki Y, Ohashi N, Matsui T, Nakayama H, Tsuboi K, et al. A randomized phase III trial exploring the prognostic value of extensive intraoperative peritoneal lavage in addition to standard treatment for resectable advanced gastric cancer: CCOG 1102 study. Jpn J Clin Oncol, 2014; 44: 101-103.
    29. Kanda M, Nomoto S, Oya H, Takami H, Hibino S, Hishida M, et al. Downregulation of DENND2D by promoter hypermethylation is associated with early recurrence of hepatocellular carcinoma. Int J Oncol, 2014; 44: 44-52.
    30. Hibino S, Kanda M, Oya H, Takami H, Shimizu D, Nomoto S, et al. Reduced expression of DENND2D through promoter hypermethylation is an adverse prognostic factor in squamous cell carcinoma of the esophagus. Oncol Rep, 2014; 31: 693-700.
    31. Kodera Y, Fujitani K, Fukushima N, Ito S, Muro K, Ohashi N, et al. Surgical resection of hepatic metastasis from gastric cancer: a review and new recommendation in the Japanese gastric cancer treatment guidelines. Gastric Cancer, 2014; 17: 206-212.
    32. Kanda M, Fujii T, Takami H, Suenaga M, Inokawa Y, Yamada S, et al. Combination of the serum carbohydrate antigen 19-9 and carcinoembryonic antigen is a simple and accurate predictor of mortality in pancreatic cancer patients. Surg Today, 2014; 44: 1692-1701.
    33. Ito T, Yamada S, Tanaka C, Ito S, Murai T, Kobayashi D, et al. Overexpression of L1CAM is associated with tumor progression and prognosis via ERK signaling in gastric cancer. Ann Surg Oncol, 2014; 21: 560-568.
    34. Kanda M, Fujii T, Takami H, Suenaga M, Inokawa Y, Yamada S, et al. Combination of the serum carbohydrate antigen 19-9 and carcinoembryonic antigen is a simple and accurate predictor of mortality in pancreatic cancer patients. Surg Today, 2014; 44: 1692-1701.
    35. Oshima Y, Tanaka H, Murakami H, Ito Y, Furuya T, Kondo E, et al. Lapatinib sensitivities of two novel trastuzumab-resistant HER2 gene-amplified gastric cancer cell lines. Gastric Cancer, 2014; 17: 450-462.
  • 2013年
    1. Kodera Y. Gastric cancer with minimal peritoneal metastasis: is this a sign to give up or to treat more aggressively? Nagoya J Med Sci, 2013; 75: 3-10.
    2. Kodera Y. Reduced port surgery for gastric cancer: another giant leap for mankind? Gastric Cancer, 2013; 16: 457-459.
    3. Murakami H, Ito S, Tanaka H, Kondo E, Kodera Y, Nakanishi H. Establishment of new intraperitoneal paclitaxel-resistant gastric cancer cell lines and comprehensive gene expression analysis. Anticancer Res, 2013; 33: 4299-4307.
    4. Nishi T, Iwasaki K, Ohashi N, Tanaka C, Kobayashi D, Nakayama G, et al. Phosphorylation of 4E-BP1 predicts sensitivity to everolimus in gastric cancer cells. Cancer Lett, 2013; 331: 220-229.
    5. Teramoto H, Koike M, Tanaka C, Yamada S, Nakayama G, Fujii T, et al. Tumor budding as a useful prognostic marker in T1-stage squamous cell carcinoma of the esophagus. J Surg Oncol, 2013; 108: 42-46.
    6. Yamada S, Fujii T, Sugimoto H, Nomoto S, Takeda S, Kodera Y, et al. Aggressive surgery for borderline resectable pancreatic cancer: evaluation of National Comprehensive Cancer Network guidelines. Pancreas, 2013; 42: 1004-1010.
    7. Oya H, Komatsu Y, Shimizu D, Koike S, Tagami K, Kodera Y. Curative surgery for gastric cancer of the elderly in a Japanese regional hospital. Hepatogastroenterology, 2013; 60: 1673-1680.
    8. Yamada S, Fujii T, Kanda M, Sugimoto H, Nomoto S, Takeda S, et al. Value of peritoneal cytology in potentially resectable pancreatic cancer. Br J Surg, 2013; 100: 1791-1796.
    9. Suenaga M, Yamada S, Fujii T, Fuchs BC, Okumura N, Kanda M, et al. A functional polymorphism in the epidermal growth factor gene predicts hepatocellular carcinoma risk in Japanese hepatitis C patients. Onco Targets Ther, 2013; 6: 1805-1812.
    10. Yamada S, Fuchs BC, Fujii T, Shimoyama Y, Sugimoto H, Nomoto S, et al. Epithelial-to-mesenchymal transition predicts prognosis of pancreatic cancer. Surgery, 2013; 154: 946-954.
    11. Takami H, Kanda M, Oya H, Hibino S, Sugimoto H, Suenaga M, et al. Evaluation of MAGE-D4 expression in hepatocellular carcinoma in Japanese patients. J Surg Oncol, 2013; 108: 557-562.
    12. Mochizuki Y, Ohashi N, Kojima H, Ishigure K, Kinoshita T, Eguchi T, et al. CPT-11 as a second-line treatment for patients with advanced/metastatic gastric cancer who failed S-1 (CCOG0702). Cancer Chemother Pharmacol, 2013; 72: 629-635.
    13. Inokawa Y, Nomoto S, Hishida M, Hayashi M, Kanda M, Nishikawa Y, et al. Detection of doublecortin domain-containing 2 (DCDC2), a new candidate tumor suppressor gene of hepatocellular carcinoma, by triple combination array analysis. J Exp Clin Cancer Res, 2013; 32: 65.
    14. Inokawa Y, Nomoto S, Hishida M, Hayashi M, Kanda M, Nishikawa Y, et al. Dynamin 3: a new candidate tumor suppressor gene in hepatocellular carcinoma detected by triple combination array analysis. Onco Targets Ther, 2013; 6: 1417-1424.
    15. Hishida M, Nomoto S, Inokawa Y, Hayashi M, Kanda M, Okamura Y, et al. Estrogen receptor 1 gene as a tumor suppressor gene in hepatocellular carcinoma detected by triple-combination array analysis. Int J Oncol, 2013; 43: 88-94.
    16. Murakami H, Nakanishi H, Tanaka H, Ito S, Misawa K, Ito Y, et al. Establishment and characterization of novel gastric signet-ring cell and non signet-ring cell poorly differentiated adenocarcinoma cell lines with low and high malignant potential. Gastric Cancer, 2013; 16: 74-83.

研究キーワード

食道癌、胃癌、大腸癌、膵癌、肝癌、クローン病、潰瘍性大腸炎